Standard BioTools (FLB) Stock Price & Analysis
FLB Stock Chart & Stats
- Day’s Range
- EUR 0.55 - EUR 0.55
- 52-Week Range
- EUR 0.53 - EUR 1.42
- Previous Close
- EUR 0.55
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 215.59M
- Enterprise Value
- -EUR 127.05M
- Total Cash (Recent Filing)
- EUR 476.72M
- Total Debt (Recent Filing)
- EUR 28.09M
- Price to Earnings (P/E)
- ―
- Beta
- 0.67
- Next Earnings
- Nov 10, 2026 (Est.)
- EPS Estimate
- -0.02
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Substantial Equity Base
The company currently has a relatively strong capital structure, with substantial equity and limited debt obligations. This reduces interest burden and provides more flexibility to fund restructuring, preserve liquidity, or pursue targeted investments while management works to stabilize the operating business.
Operational Restructuring Is Improving Cost Performance
Improving gross margins and a materially smaller adjusted EBITDA loss indicate that cost-cutting and productivity actions are beginning to affect operating performance. If sustained, these gains can reduce the scale of losses and improve the earnings potential of the remaining portfolio.
Portfolio Divestitures Are Sharpening Strategic Focus
Selling non-core or less strategically aligned businesses can simplify the operating model and concentrate resources on the company’s highest-priority life science tools activities. A narrower portfolio may improve execution discipline and clarify the company’s long-term market positioning.
Bears Say
Persistent Losses And Substantial Cash Burn
The company is consuming significant cash while generating large operating losses, making financial improvement dependent on a sustained turnaround. Continued burn can reduce reserves over time and may constrain investment capacity or increase reliance on asset sales and external funding.
Severe And Volatile Revenue Contraction
A shrinking and volatile revenue base makes it difficult to absorb the company’s operating cost structure and sustain recent margin improvements. Persistent demand or product-mix weakness could delay breakeven, reduce scale benefits, and weaken the durability of the business model.
Nasdaq Bid-price Deficiency Creates Compliance Risk
The Nasdaq deficiency is a structural corporate risk because failure to regain compliance could lead to delisting or force a reverse split. Either outcome could complicate investor access, increase execution pressure, and distract management during an already significant restructuring.
Standard BioTools News
FLB FAQ
What was Standard BioTools’s price range in the past 12 months?
What is Standard BioTools’s market cap?
When is Standard BioTools’s upcoming earnings report date?
How were Standard BioTools’s earnings last quarter?
Is Standard BioTools overvalued?
Does Standard BioTools pay dividends?
What is Standard BioTools’s EPS estimate?
How many shares outstanding does Standard BioTools have?
What happened to Standard BioTools’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Standard BioTools?
What is the TipRanks Smart Score and how is it calculated?
Standard BioTools Stock Smart Score
Company Description
Standard BioTools
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Specialties
- CEO
- Michael Egholm
- Employees
- 387
- Website
- www.standardbio.com
- Address
- 50 Milk Street, Boston, MA, 02109, US
Standard BioTools (FLB) Earnings & Revenues
FLB Earnings Call
Earnings Call SentimentNeutral
The earnings call reflected a well-managed quarter with robust strategic initiatives and strong cost management, despite facing significant revenue declines and challenges in the U.S. academic market. The company's strong cash position and strategic product expansions provide a positive outlook, though the impact of tariffs and revenue declines remain concerns.
View all DE:FLB earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 5 | 12 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 2 | 0 | 10 |
